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Ceramide mediates apoptosis and is upregulated by oxidative stress. To reveal the causative agent of
diabetes-induced complications, we examined the changes in ceramide metabolism during diabetes.
Two and 8 weeks after intraperitoneal injection of streptozotocin (STZ: 40 mg kg1 body weight) to
rats, tissue ceramide levels were analyzed by liquid chromatography-electrospray tandem mass
spectrometry (LC-MS/MS). Blood glucose was significantly increased 2 weeks after STZ
administration. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea
nitrogen (BUN) levels were also increased in the diabetic rats, suggesting that hepatic and renal damage
was induced by STZ administration. Vitamin C, an indicator of oxidative stress, was significantly
decreased in the plasma, liver, and kidney of rats 2 weeks after STZ administration. Although no
differences in hepatic ceramide levels were observed between the control and diabetic rats, plasma and
renal ceramide levels were significantly increased 8 weeks after STZ administration. In the liver and
kidney, acid and neutral sphingomyelinase (SMase) activities were not increased, while secretory
sphingomyelinase (sSMase) activity was increased in the plasma of diabetic rats after STZ
administration. These data indicated that STZ administration induced the increase in plasma ceramide
levels via the increase in sSMase activity. It was suggested that increased plasma ceramide levels were
involved in the renal damage induced by STZ in diabetic rats accompanied with the enhancement of
oxidative stress.
Introduction
Diabetes mellitus and its complications (such as nephropathy,
atherosclerosis, retinopathy, neuropathy, and so on) are serious
worldwide concerns in public health. Diabetes mellitus is
a metabolic disease characterized by hyperglycaemia, and
chronic hyperglycaemia and reactive oxygen species (ROS) are
increased through non-enzymatic glycosylation and glucose
autoxidation.1 Oxidative stress has been implicated in the
development and progression of various diabetes-induced
complications2 and antioxidants decrease diabetes-induced
complications by ameliorating the damage by free radicals.3
Treatment of rats with the beta-cell toxin streptozotocin (STZ)
results in a diabetic state characterized by insulin deficiency and
is used as a model of type 1 diabetes.4 Generation of ROS is
involved in cytotoxic actions in STZ-induced diabetic rats,5,6 and
STZ administration causes diabetes-induced complications in
various tissues including the liver and kidney.7,8 It is possible that
toxic materials are increased by the enhanced oxidative stress
during diabetic conditions, thereby damaging the liver and
kidney.
Ceramide has been implicated in regulating cell cycle arrest,
apoptosis, and cellular senescence,9 and serves as an intracellular
second messenger in these processes.10 Oxidative stress such as
UV light, antineoplastic drugs and radiation induces ceramide
accumulation in cells.11–14 Ceramide is generated from sphingo-
myelin (SM) by sphingomyelinase (SMase), which is classified
based on pH optimum, subcellular localization, and cation
dependency.13,15 Neutral SMase (nSMase) is localized in the
plasma membrane and exhibits an optimal pH of around 7.5 and
Mg2+ dependence. Acid SMase (aSMase), with an optimal pH of
4.8, operates in the endosomal–lysosomal compartments or
plasma membrane. Lysosomal and secretory SMase (sSMase) is
derived from aSMase by differential protein trafficking of
a common protein precursor,16 and sSMase is secreted by the
vascular endothelium and macrophages and is the only enzyme
responsible for sphingolytic activity in the plasma.17
We previously reported that the ceramide level in the plasma,
liver, and kidney was increased via nSMase activation when
oxidative stress was induced by CCl4 intoxication in rats.
18,19 In
addition, other studies have demonstrated that SMase activation
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and the increase in ceramide levels were important participants in
atherosclerosis.20,21 Hyperglycaemia causes increased production
of ROS in all tissues and plays a role in the development of
complications in diabetes mellitus.22,23 A recent study demon-
strated that the ceramide level was elevated in the plasma of
patients with type 2 diabetes.24 Therefore, in the STZ-induced
diabetic rats, ceramide may also be a putative mediator of lip-
otoxicity in diabetes-induced complications. In order to find
a target enzyme to prevent diabetic complications, we investi-
gated whether ceramide metabolism was altered in damaged
tissues by STZ administration, and whether ceramide accumu-
lation is correlated with the pathogenesis of diabetes-induced
complications.
Results
Changes in blood glucose levels, ALT and AST activities, and
blood urea nitrogen levels
This study was approved by the Animal Care Committee of Nara
Women’s University. The blood glucose level in the diabetic
group after STZ administration was significantly higher than
that in the control group (Fig. 1a). Within the control and
diabetic groups, no differences in blood glucose levels at 2 and 8
weeks were observed. To examine the effect of STZ administra-
tion on hepatic and renal injury, we analyzed alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
activities and blood urea nitrogen (BUN) levels. Plasma AST and
ALT levels were significantly increased by STZ administration
(Fig. 1b and c). These levels at 8 weeks in the diabetic rats were
further increased. At 2 weeks, the BUN levels in the control
group were almost equal to those in the diabetic group. However,
these levels in the diabetic rats at 8 weeks were significantly
higher than those in the other groups (Fig. 1d).
Effect of STZ administration on vitamin C level in plasma, liver,
and kidney
In the liver and kidney, the vitamin C level in the diabetic rats was
significantly decreased 2 and 8weeks after STZ administration. In
the diabetic rats, the hepatic and renal vitamin C levels at 8 weeks
were significantly lower than those at 2 weeks (Fig. 2a and b).
Although no significant differences were observed in plasma
vitamin C levels between the control and diabetic groups at 2
weeks, the diabetic rats exhibited a significant decrease in plasma
vitamin C compared with the control group at 8 weeks (Fig. 2c).
Fig. 1 Changes in blood glucose levels (a), plasma AST (b) and ALT (c) activities, and BUN levels (d) in STZ-induced diabetic rats. Values are mean
SEM (n ¼ 5 or 6 in each group). *Significant difference between the control and diabetic groups (p < 0.05). #Significant difference between the 2- and 8-
week groups (p < 0.05).
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Effect of STZ administration on ceramide level in the liver,
plasma, and kidney
Tissue ceramide concentration was determined using LC-MS/
MS as described previously.14,18 In the liver, the major ceramides
were C24:0 and C24:1 (Fig. 3a). STZ administration did not
increase hepatic ceramide levels except for that of C16:0 at 8
weeks. However, in the diabetic rats, C24:1 and C24:2 levels were
significantly increased at 8 weeks compared with those at 2
weeks.
Fig. 2 Effect of STZ administration on the level of vitamin C in the liver (a), kidney (b), and plasma (c) of the control and diabetic rats. Values are mean
 SEM (n ¼ 5 or 6 in each group). *Significant difference between the control and diabetic groups (p < 0.05). #Significant difference between 2- and
8-week groups (p < 0.05).
Fig. 3 Effect of STZ administration on the level of ceramide in the liver (a), kidney (b), and plasma (c) of the control and diabetic rats. Values are mean
 SEM (n ¼ 5 or 6 in each group). *Significant difference between the control and diabetic groups (p < 0.05). #Significant difference between 2- and
8-week groups (p < 0.05).
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C24:0 and C24:1 were also found to be major ceramides in the
kidney (Fig. 3b). Levels of long-chain fatty acid ceramides such
as C22:0, C24:0, C24:1, and C24:2 and total ceramides in
the kidney in the diabetic rats were higher than those in the
control rats at 2 weeks. The levels of these ceramides were
further increased and a significant difference was also observed
between the control and diabetic groups 8 weeks after STZ
administration.
The major ceramides in the plasma were C24:0 and C24:1 in
the control and diabetic rats (Fig. 3c). Plasma C16:0 levels in the
diabetic rats at 2 weeks were increased compared to the control
rats, and total plasma ceramide levels in the diabetic rats were
higher than those in the control rats at 8 weeks. In the diabetic
groups, the total plasma ceramide levels at 8 weeks were signif-
icantly higher than those at 2 weeks.
Changes in the SMase activity in STZ-induced diabetic rats
SMase, which directly generates ceramide, is a key regulatory
step in the ceramide-signalling cascade.9 In the liver, STZ
administration did not affect nSMase activity at 2 or 8 weeks
(Fig. 4a). After 2 weeks, hepatic aSMase activity in the diabetic
group was significantly lower than that in the control group
(Fig. 4b). Although renal nSMase activity in the diabetic rats was
higher than that in the control rats at 2 weeks (Fig. 4c), aSMase
activity in the diabetic group at 2 and 8 weeks was lower
compared to that in the control group (Fig. 4d). Because the
plasma ceramide level was increased in STZ-induced diabetic
rats, sSMase activity was measured. Plasma sSMase activity was
found to be significantly increased 2 and 8 weeks after STZ
administration compared to that in the control group (Fig. 4e).
Discussion
Ceramide has been implicated in various diseases such as
atherosclerosis,25,26 which accompanies enhanced oxidative
stress. STZ injection in animals produces various kinds of ROS
such as superoxide, hydroxyl radical, and lipid hydroperoxides.5–8
In this study, we examined whether STZ administration caused
tissue damage and affected ceramide metabolism at 2 weeks
(early) and 8 weeks (advanced stage) during the progression of
oxidative stress.
Chronic hyperglycaemia occurring in uncontrolled diabetes
leads to significant long-term damage and failure of various
organs. STZ-induced diabetic rats also exhibit many complica-
tions observed in human diabetic patients.27 Our results
demonstrated that plasma ALT and AST levels were significantly
augmented 2 weeks after STZ injection and further increased
after 8 weeks, showing signs of liver injury as early as 2 weeks
after STZ administration. A major complication of diabetes is
renal disease such as nephropathy.2 In this study, we also
demonstrated that the plasma BUN level 8 weeks after STZ
administration was significantly increased in the diabetic group
compared to the control group, showing that STZ injection
induced diabetes-induced complications in the rat kidney.
Similar increases in BUN and ceramide levels in the plasma and
kidney have been reported under severe oxidative stress leading
to renal failure during fulminant hepatic failure induced by CCl4
intoxication.18
Diabetic mellitus induces a requirement for antioxidants such
as vitamin C28 and enhancement of oxidative stress induces the
development of diabetes. Our previous studies have showed that
the concentrations of vitamin C, which is an outstanding hydro-
philic antioxidant in tissues and is consumed primarily under
conditions of enhanced oxidative stress, most sensitively reflects
oxidative stress in the rat liver during chemical intoxication.29 In
this study, the liver vitamin C level was significantly decreased 2
weeks after STZ injection, showing that oxidative stress was
enhanced in the liver. Therefore, the decrease in the level of
antioxidants such as vitaminCmay induce the liver injury in STZ-
induced diabetic rats similar to chemically induced hepatitis18,30,31
where hepatic vitamin C levels are decreased by a similar extent.
We have previously demonstrated that hepatic ceramide levels
and nSMase activity were increased by CCl4 administration,
which enhances oxidative stress.18,19However, in this study, using
STZ-induced diabetic rats, the hepatic ceramide level was almost
identical to that in the control group, and hepatic nSMase and
aSMase activities were not increased in diabetic rats compared
with control rats. Although the hepatic ceramide level was
increased in a rat model of type 2 diabetes,24,32 our results indi-
cated that the hepatic damage in type 1 diabetic rats was not due
to ceramide accumulation. These results suggested that the
enhancement of oxidative stress via hyperglycaemia led to liver
dysfunction, and that the ceramide accumulation was not asso-
ciated with the pathogenesis of liver injury in the STZ diabetic
rats at least 8 weeks after STZ administration.
Hyperglycaemia augments oxidative stress in the plasma due
to the overproduction of free radicals and decreased efficiency of
the antioxidant defense system. In this study, the plasma vitamin
C level was decreased as early as 2 weeks after STZ adminis-
tration and its level remained at this low level 8 weeks after STZ
administration. Two weeks after STZ administration, only
plasma C16:0 ceramide was significantly increased and this
increase may correspond to the elevation of plasma sSMase
activity. However increase in other ceramides was not observed.
This result suggests that catabolism system of ceramide for
example in the kidney still effectively operated at the early phase
of diabetes. At 8 weeks the levels of all species of plasma
ceramide were elevated, and the activity of plasma sSMase, the
only sphingolytic enzyme in plasma, was significantly increased
following STZ administration. Therefore, the increase in plasma
ceramide level by STZ injection may be ascribed to the elevated
sSMase activity. STZ-induced-b-cell destruction mediates the
release of cytokines such as TNF-a,33 and that sSMase secretion
from endothelial cells is stimulated by a variety of proin-
flammatory mediators such as TNF-a.34 Therefore, the increase
in plasma sSMase activity might be stimulated by increased
cytokine production.
Renal damage was confirmed based on BUN levels 8 weeks
after STZ administration when low concentration of renal
vitamin C was maintained. Kashiba et al.35 reported the impaired
regeneration of renal vitamin C and urinary excretion of vitamin
C were increased following STZ injection. Consistent with this
study, which demonstrated that STZ administration induced
renal deterioration along with the decrease of vitamin C, anti-
oxidant supplements were found to inhibit the increased
ROS production and effectively prevent renal dysfunction in
STZ-induced diabetic rats.36 Because the cellular uptake of
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vitamin C is promoted by insulin and inhibited in conditions such
as hyperglycaemia,37 it is reasonable that vitamin C treatment
significantly decreased BUN levels in diabetic rats.38 Therefore,
the enhancement of oxidative stress is an important factor leading
to the development of renal damage at an advanced stage.
In the kidney, all long-chain fatty acid-bound ceramides
except C16:0 and C18:0 were increased in STZ-induced diabetic
rats. Therefore, accumulation of these ceramides may also
contribute to the renal damage. In this study, renal nSMase and
aSMase activities did not increase in the diabetic rats at 8 weeks
compared with those in control rats, suggesting that increased
ceramide levels at the advanced stage of diabetes were not due to
the production but the transport of ceramides from the plasma.
These results imply that ceramide accumulation is a cause of
renal dysfunction in STZ-induced diabetic rats.
Conclusions
Ceramide accumulation was induced in the plasma and kidney of
STZ-induced in diabetic rats, and accompanied by a decrease in
vitamin C levels. Furthermore, elevated sSMase activity was
suggested to be involved in the increase in plasma ceramide
levels. Thus, the increase in plasma ceramide levels may play an
important role in the pathogenesis of diabetes-induced
Fig. 4 Effect of STZ administration on nSMase activity in the liver (a) and kidney (c), aSMase activity of liver (b) and kidney (d), and sSMase activity
(e) in the control and diabetic rats. Values are mean  SEM (n ¼ 5 or 6 in each group). *Significant difference between the control and diabetic groups
(p < 0.05). #Significant difference between 2- and 8-week groups (p < 0.05).
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complications. Therefore sSMase is a possible target to develop
an inhibitor for the prevention of diabetic complications.
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